Maxillofacial Diseases

Sep 26, 2024 | bmcpublichealth.biomedcentral.com | Xi’an Jiaotong |Maxillofacial Diseases

This study used data from NHANES, a publicly available database that collects comprehensive information on health, diet, and lifestyle through interviews, physical examinations, and laboratory tests. The study population comprised 11,552 individuals selected from NHANES 2007–2020 after excluding incomplete data (Fig. 1). Depression was assessed using the Patient Health Questionnaire (PHQ-9), a self-reported tool that measures the severity of depressive symptoms.

Aug 21, 2024 | academic.oup.com | Inner Mongolia |Maxillofacial Diseases |Xi'an Jiaotong |Xi’an Jiaotong

This study aims to address challenges in dental pulp regeneration therapy. The heterogeneity of DPSCs poses challenges, especially in stem cell transplantation for clinical use, particularly when sourced from donors of different ages and conditions. Pseudotime analysis was employed to analyze single-cell sequencing data, and immunohistochemical studies were conducted to investigate the expression of fibronectin 1 (FN1). We performed in vitro sorting of PDGFRβ+ DPSCs using flow cytometry.

Jun 30, 2024 | onlinelibrary.wiley.com | Caique Mariano Pedroso |Omar Kujan |Tuula Anneli Salo |Maxillofacial Diseases

DATA AVAILABILITY STATEMENT The authors confirm that all the data supporting the results of this review are available within the article or in its supplementary materials.

Dec 21, 2023 | academic.oup.com | Xi’an Jiaotong |Maxillofacial Diseases

This study aimed to investigate the genetic polymorphisms and population characteristics of the Mongolian group from northwest China (NCM) through the self-developed panel of 43 autosomal insertion/deletion (A-InDel) polymorphism genetic markers. Herein, 288 unrelated healthy individuals from the NCM group were employed to obtain the genetic data of 43 A-InDels through PCR amplification and InDel genotyping.

Aug 14, 2023 | bmccancer.biomedcentral.com | Maxillofacial Diseases |Biocenter Oulu

The experimental protocol for use of OTSCC patient samples was approved by the Ethics Committee of the Northern Ostrobothnia Hospital District, Finland (statement no. 31/2016). Four primary (OU-OTSCC-7A, OU-OTSCC-9A, OU-OTSCC-18A, OU-OTSCC-15A) and three metastatic (OU-OTSCC-7B, OU-OTSCC-9B, OU-OTSCC-18B) tumour cell lines were isolated from OTSCC patient samples at Oulu University Hospital after informed consent.